SHENZHEN, China, March 31, 2026
SHENZHEN, China, March 31, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group"; stock code: 1302.HK), a leading medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its audited consolidated results for the year ended 31 December 2025 (the "Reporting Period").
Note [1]: Such non-recurring items include (i) the share-based payment expenses; (ii) the other gains and losses resulting from financial assets at fair value through profit or loss ("FVTPL"); and (iii) the changes in fair value of the financial liabilities at FVTPL related to the redeemable shares of Biotyx Medical (Shenzhen) Co., Ltd.
Domestic Market Maintains Steady Growth, Overseas Business Posts Considerable Growth
In 2025, the Group steadily advanced in a complex and ever-changing market environment, continuously consolidating its leading position in the domestic market while accelerating its expansion into international markets.
Driven by its dual core strategies of "Innovation" and "Internationalization", the Group focused on addressing unmet global clinical needs and leveraged its global sales network to enhance synergies across branding, patents, distribution channels, clinical registration, and global operations. Domestically, it further strengthened its market foundation through broader adoption of its innovative product portfolio. Internationally, it earned wider recognition, achieving sustained and considerable growth in overseas revenue.
The domestic market performed steadily, with sales increasing by approximately 1.7% year-on-year, accounting for about 71.1% of the Group's total revenue. Overseas sales of the Group grew by approximately 14.4% year-on-year, accounting for approximately 28.9% of the total revenue.
In particular, the European market recorded a strong growth of approximately 25.9%, becoming the Group's largest overseas market and contributing approximately 12.1% of the total revenue.
Core Business Demonstrates Resilience
The Group currently operates three main product lines, including the Structural Heart Diseases (SHD) business, the Peripheral Vascular Diseases (PVD) business and the Cardiac Pacing and Electrophysiology (CPE) business.
The revenue of the Group was approximately RMB1,369.8 million during the Reporting Period, representing a year-on-year growth of approximately 5.1%. This increase was mainly due to the increase in revenue from the sales of stent grafts, which rose by approximately 19.9% year-on-year.
SHD Business
The Group has established a diversified product portfolio in the SHD business, mainly including Left Atrial Appendage (LAA) occluders and three generations of congenital heart diseases occluders, aiming to address various market demands through differentiated product strategies.
During the Reporting Period, the sales contributed by the SHD business were approximately RMB511.7 million, representing a year-on-year decrease of approximately 3.0%. Continuous technological innovation and product upgrades will further enrich the Group's SHD product portfolio and enhance its global sales layout.
PVD Business
The Group is striving to provide global patients with technology-leading systematic and comprehensive interventional medical devices solutions to treat peripheral vascular diseases. Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts, Iliac artery bifurcation stent grafts, aortic stent graft system, aortic arch stent graft system and thoracoabdominal artery stent graft system.
During the Reporting Period, the sales contributed by the PVD business were approximately RMB844.6 million, representing a year-on-year growth of approximately 12.4%.
CPE Business
The Company is the first manufacturer in China that has a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions.
During the Reporting Period, the sales contributed by the CPE business were approximately RMB13.5 million.
Research and Development
The Group adheres to independent innovation, aiming to provide medical devices with outstanding clinical value for patients and physicians worldwide. In 2025, the Group continuously strengthened its innovation capabilities and accelerated the development of products to maintain its leading position in the industry.
During the Reporting Period, the R&D investment (including capitalized expenditure) of the Group amounted to approximately RMB329.0 million, accounting for about 24.0% of the total revenue, leading to the following key milestones:
Intellectual Property Rights
Intellectual property is an internal driving force to improve our core competitiveness in the medical device market. As at 31 December 2025, the Group had filed a total of 2,631 valid patent applications worldwide, of which 1,217 patents had been granted.
Strategic Collaboration to Enter Electrophysiology Market
On 6 June 2025, the Company, through its wholly-owned subsidiary Lifetech Shenzhen, entered into a series of agreements to invest RMB150.0 million in Affector Medtech (Suzhou) Ltd. ("Affector Medtech"). Upon completion of all stages of the investment, Lifetech Shenzhen will hold 30% equity interest in Affector Medtech. As of 31 December 2025, Lifetech Shenzhen has completed the first stage of capital injection, for a consideration of RMB100.0 million in cash, and holds a 22.22% equity interest in Affector Medtech.
Through this strategic investment, the Group has secured exclusive priority cooperation rights and exclusive overseas distribution rights for Affector Medtech's electrophysiology related products, as well as both parties will jointly promote the research, development and commercialization of innovative cardiac interventional imaging platform products. This has further expanded our presence in the high-growth medical device sector, enhanced our technological capabilities, and generated synergies with our existing businesses.
The Chairman and CEO of LifeTech, Mr. XIE Yuehui, said:
"In 2025, the Group continued to forge ahead steadily amidst the global wave of industry transformation and development. Leveraging our strong business resilience and the synergies among our specialized business segments, we continue to drive sustainable growth. We strengthened our market presence, expanded internationally, and reached significant milestones in product research and development as well as clinical translation. Meanwhile, the strategic investment in Affector Medtech has positioned us in the fast-growing electrophysiology market, unlocking new growth opportunities through strong synergies.
Guided by our core strategies of 'innovation' and 'internationalization', we will continue to accelerate product development and clinical application, drive technological breakthroughs, and provide comprehensive solutions for diverse clinical needs. At the same time, we aim to strengthen our global business, sustainably grow our global market share, and further solidify our industry leadership.
In light of the vast opportunities in the global healthcare industry, the Group is full of confidence. Leveraging our outstanding innovation capabilities, solid industrial foundation, and growing global influence, we are well-positioned to navigate challenges in a complex and ever-changing market, seize new development opportunities, and embark on a journey toward sustainable, high-quality growth. Through impactful innovation and positive social contributions, we aim to create greater value for patients, physicians, shareholders, and all other stakeholders."
About LifeTech Scientific Corporation
Established in 1999 in Shenzhen, China, LifeTech Scientific Corporation (Stock Code: 1302.HK) specializes in the R&D, manufacturing, and sales of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurovascular conditions. It also possesses the world's first innovative iron-based bioabsorbable material technology platform.
Guided by the core strategy of "innovation" and "internationalization", LifeTech Scientific maintains a leading market position for its key products in the home country and has established 7 subsidiaries overseas, extending its sales network to nearly 120 countries and regions worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lifetech-scientific-corporation-announces-2025-annual-results-steady-revenue-growth-with-adjusted-net-profit-increasing-24-9-302730371.html
SOURCE LifeTech Scientific Corporation
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
